Small Molecules for Precision Medicine

Learn More about Arqule

We are pursuing multiple programs in biomarker-defined oncology and rare disease indications

Targeted Approach to Cancer

Clinical Trials

Research & Development

Product Pipeline

Targeted Approach To

Rare Diseases

News & Events

September 29, 2017

Proteus Syndrome Phase 1 Data Presentation

November 13, 2019

ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019

November 25, 2019

ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting

More News & Events »